Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results Heron Therapeutics (NASDAQ: HRTX) reported $154.9 million net revenue for 2025, driven by a 65.1% year‑over‑year rise in its Acute Care franchise. The company issued 2026 guidance of $173–$183 million net revenue and $10–$20 million adjusted EBITDA.Key 2025 items: APONVIE and ZYNRELEF growth, CMS product‑specific J‑Codes for both products, completion of the ZYNRELEF vial access needle transition, Oncology revenue of >$105 million, and cash of $46.6 million at year end.

#HRTX Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/HRTX/heron-therapeu...

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth Heron Therapeutics (Nasdaq: HRTX) reported preliminary, unaudited net revenue of approximately $40.5 million for Q4 2025 and $154.9 million for full-year 2025. Key Q4 contributors were ZYNRELEF (~$12.5M), CINVANTI (~$22.9M), APONVIE (~$3.8M) and SUSTOL (~$1.3M).ZYNRELEF delivered the largest quarter-over-quarter increase in the portfolio in Q4, rising ~35% vs Q3 2025. Management highlighted momentum in the Acute Care franchise across ZYNRELEF and APONVIE and described continued progress across the business during 2025.

#HRTX Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

www.stocktitan.net/news/HRTX/heron-therapeu...

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 million ZYNRELEF ® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the

#HRTX Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

www.stocktitan.net/news/HRTX/heron-therapeu...

$1.37 Billion Tax Asset Protection: Heron Therapeutics Adopts Strategic Rights Plan to Preserve NOLs Biotech firm Heron Therapeutics establishes Section 382 rights plan to protect $1.37B in federal NOLs from ownership changes. Plan restricts investors from acquiring 4.99%+ stake.

#HRTX Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

www.stocktitan.net/news/HRTX/heron-therapeu...

Trade Alerts, Wednesday August 13, 2025 – Crystal Equity Research

Small-cap stocks oversold with improving relative strength, Wed Aug 13th - #CYCA #MURA #LGVN #IBIO #HRTX #FNKO #FAT #ACXP #TIC #FVRR - More: crystalequityresearch.com/trade-alerts... - #smallcap

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile Heron Therapeutics (NASDAQ: HRTX) has completed a comprehensive capital restructuring to enhance financial flexibility and reduce debt. The multi-faceted refinancing includes: a $110 million senior credit facility from Hercules Capital (with additional $40 million available in milestone-based tranches), retirement of existing convertible notes through $125 million cash repayment and $25 million stock conversion, issuance of $35 million new convertible notes, and a $27.7 million private placement.The restructuring aims to eliminate near-term debt maturities and provide working capital for commercial and development initiatives. The transactions, initiated on August 8, 2025, are expected to close on August 12, 2025.

#HRTX #HTGC Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

www.stocktitan.net/news/HRTX/heron-therapeu...

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress Heron Therapeutics (NASDAQ:HRTX) reported strong Q2 2025 financial results with total net revenue of $37.2 million, a 3.3% increase year-over-year. The company's Acute Care franchise showed impressive growth of 55.5% year-over-year in Q2 2025.Key highlights include ZYNRELEF unit demand growth of 6.3% and APONVIE unit demand growth of 19% in Q2 compared to Q1 2025. The company completed a capital restructuring, reducing total debt from $175M to $145M and extending maturities to 2030.Heron raised its 2025 Adjusted EBITDA guidance to $9.0-$13.0 million from $4.0-$12.0 million, while reaffirming net revenue guidance of $153-$163 million. The company ended Q2 with $40.6 million in cash and equivalents.

#HRTX Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

www.stocktitan.net/news/HRTX/heron-therapeu...

Heron Therapeutics Accelerates Q2 2025 Earnings Release: New Date and Key Details Revealed Heron Therapeutics advances Q2 2025 earnings call to August 8 at 8:30 AM ET, three days earlier than planned. Get the new conference details.

#HRTX Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

www.stocktitan.net/news/HRTX/heron-therapeu...

Heron Therapeutics Hits Record Q1 EBITDA, Boosts 2025 Outlook After 89% Acute Care Growth Q1 delivers $6.2M record EBITDA with 12.2% revenue growth. Patent settlement extends exclusivity to 2032. See updated guidance and growth drivers.

#HRTX Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

www.stocktitan.net/news/HRTX/heron-therapeu...

Heron Therapeutics Wins 7-Year Market Exclusivity in Patent Settlement with Mylan Patent settlement grants Mylan generic rights to CINVANTI and APONVIE starting 2032, protecting Heron's market exclusivity. See settlement details.

#HRTX Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

www.stocktitan.net/news/HRTX/heron-therapeu...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Mon May 5th- #CATO #SQNS #UFI #FLGC #HRTX #SDST #WHWK #NTCL #PITX #NXL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Heron Therapeutics Posts First Profitable Quarter: Can ZYNRELEF's Expansion Fuel Continued Growth? Heron reports Q4 net income of $3.6M and full-year revenue of $144.2M. ZYNRELEF expands to 17M potential procedures with extended CMS payment status through 2027.

#HRTX Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

www.stocktitan.net/news/HRTX/heron-therapeu...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish crossover of moving average convergence divergence signal, Mon Feb 10th - #XPEL #WPRT #UFPT #TBPH #SEVN #RZLT #PCRX #OCCI #MERC #JRVR #HRTX #ELTX #DCTH #CCSI #BDTX #UNFI #SMWB #GGT #DHT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Heron Therapeutics Relocates HQ to Research Triangle Park, Marking Strategic Biotech Hub Move Biotech firm Heron Therapeutics strategically shifts headquarters to North Carolina's prestigious Research Triangle Park, centralizing operations for enhanced growth potential.

#HRTX Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

www.stocktitan.net/news/HRTX/heron-therapeu...

#OptionsTrading
Happy Trading!
Individual Stocks
#OKTA
Watching for $92.00 to hold as support on any pullback and for a push to test $100.00.

#MRVL
Watching for $98.72 to hold as support on any pullback and then draw out the fibs.

#HRTX
Watching for $1.80 to hold as support

BREAKING NEWS: ( NASDAQ: #HRTX ) District Court Rules in Favor of Heron in CINVANTI Patent Lawsuit

#StockMarket #News

Heron Therapeutics Wins Major Patent Battle Over CINVANTI, Blocks Generic Until 2035 | HRTX Stock News Delaware Court upholds Heron's CINVANTI patents in lawsuit against Fresenius Kabi, preventing generic competition for the injectable emulsion until 2035.

#HRTX U.S. District Court Upholds Validity of CINVANTI® Patents

#stocks #investing #news

www.stocktitan.net/news/HRTX/u-s-district-c...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IBIT, #AMCR, #HRTX, #NOV, #UWMC

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IBIT 18.2x
2. #AMCR 7.6x
3. #HRTX 3.2x
4. #NOV 2.4x
5. #UWMC 2.2x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CPNG, #HRTX, #PCAR, #ORC, #PGY

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CPNG 10.6x
2. #HRTX 2.7x
3. #PCAR 2.6x
4. #ORC 2.1x
5. #CORZ 2.1x

#OptionFlow #OptionsTrading #Trading